Antidiabetic action and significant cell viability of bezafibrate-in HEPG2 cell line analysis compared with a biguanide-A potential in the treatment of metabolic syndrome/syndrome X

Susshmitha R, Arul Amutha, Arv

Abstract

Metabolic Syndrome (MetS) has been highlighted as a major socioeconomic problem throughout the world as the burden of MetS along with its individual risk factors-central obesity, insulin resistance, dyslipidaemia, and hypertension is evident throughout all ethnicities studies. This study was conducted to evaluate the anti-diabetic property and the cell viability of Bezafibrate, an activator of Lipoprotein Lipase(LPL), when compared to a standard drug used in the treatment of type II Diabetes Mellitus, Metformin ( Biguanide – Oral Hypoglycaemic Agent). In-Vitro analysis with HepG2 tissue culture was done. Glucose consumption of the test drug Bezafibrate was analysed using Glucose oxidase method and the cell viability was determined by MTT [3-(4, 5-dimethylthiazol-2-yl)- 2, 5-diphenyl tetrazolium bromide] assay. The test drug Bezafibrate showed increased glucose consumption level in HepG2 cell lines and had a higher cell viability percentage than the control drug, Metformin.